The invention relates to a method for preparing nebivolol and more particularly to an improved method for the synthesis of an alpha-haloketone of the formula (I) which is a key intermediate in the preparation of nebivolol.

The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I) without the use of wetting agent and optionally u...

A pharmaceutical composition of levamlodipine or a pharmaceutically acceptable salt thereof and a p receptor blocking agent and a use thereof are provided. An active ingredient of the pharmaceutical composition contains levamlodipine or a pharmaceutically 5 acceptable salt thereof and a p receptor blocking agent in which the P receptor blocking agent is one selected from nebivolol bisoprolol betaxolol celiprolol and nadolol. A use of the pharmaceutical composition in preparation of a medicine fo...

The present invention relates to a novel process for the synthesis of the Nebivolol product depicted in Scheme 1 comprised of a reduced number of high-yield steps and characterized by the enzymatic resolution of the chroman ester precursor.

The present invention relates to modified nebivolol formate useful in the preparation of highly pure nebivolol.

The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I), without the use of wetting agent, and optionall...

The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I) without the use of wetting agent and optionally u...

The present invention relates to a novel process for the synthesis of the Nebivolol product depicted in Scheme 1 comprised of a reduced number of high-yield steps and characterized by the enzymatic resolution of the chroman ester precursor.

The present invention relates to modified nebivolol formate useful in the preparation of highly pure nebivolol.